quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·1d
PRRelease
Merck & Company Inc. logo

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

MRK· Merck & Company Inc.
Health Care
Original source

Companies

  • MRK
    Merck & Company Inc.
    Health Care

Recent analyst ratings

  • Feb 25UpdateRBC Capital Mkts$142.00
  • Feb 20UpdateBarclays$140.00
  • Feb 13UpdateDeutsche Bank$150.00
  • Jan 8UpdateWolfe Research$135.00
  • Dec 18UpdateBMO Capital Markets$130.00
  • Nov 24UpdateWells Fargo$125.00

Related

  • PR2d
    FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
  • PR6d
    European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
  • PR8d
    New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
  • PR10d
    Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
  • SEC15d
    SEC Form DEFA14A filed by Merck & Company Inc.
  • SEC15d
    SEC Form DEF 14A filed by Merck & Company Inc.
  • PR16d
    Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
  • PR21d
    Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022